

Mesoblast Ltd (MSB) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/M79A7626DDCEN.html>

Date: September 2018

Pages: 52

Price: US\$ 125.00 (Single User License)

ID: M79A7626DDCEN

Abstracts

Mesoblast Ltd (MSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft versus host disease; MPC-06-ID, for the treatment of chronic low back pain (CLBP); and MPC-300-IV for the treatment of chronic inflammatory conditions such as biologic-refractory rheumatoid arthritis, and diabetic nephropathy. Mesoblast conducts clinical trials in areas including cardiac diseases, spinal orthopedic disorders, cancer, hematological conditions, and immune-mediated and inflammatory conditions. The company has operational presence in the US and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Mesoblast Ltd Key Recent Developments

Sep 17,2018 TOPC: Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire: MarketLine - GNW]

Aug 30,2018 Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results

and Operational **Highlights**

Aug 28,2018 Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group

Jul 11,2018 Mesoblast Names Shawn Cline Tomasello As Board Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Mesoblast Ltd - Key Facts
Mesoblast Ltd - Key Employees
Mesoblast Ltd - Key Employee Biographies
Mesoblast Ltd - Major Products and Services
Mesoblast Ltd - History
Mesoblast Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Mesoblast Ltd - Business Description
Mesoblast Ltd - Corporate Strategy
Mesoblast Ltd - SWOT Analysis
SWOT Analysis - Overview
Mesoblast Ltd - Strengths
Mesoblast Ltd - Weaknesses
Mesoblast Ltd - Opportunities
Mesoblast Ltd - Threats
Mesoblast Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

Mesoblast Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 17, 2018: TOPC: Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire: MarketLine - GNW]

Sep 17, 2018: TOPC: Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire: MarketLine - GNW]

Sep 17, 2018: TOPC: Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire: MarketLine - GNW]

Sep 17, 2018: TOPC: Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire: MarketLine - GNW]

Sep 17, 2018: TOPC: Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast[Newswire: MarketLine - GNW]

Aug 30, 2018: Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights

Aug 28, 2018: Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group

Jul 02, 2018: Mesoblast Enters Into US\$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-I in the Treatment of Acute Graft Versus Host Disease

May 31, 2018: Mesoblast Reports Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018

May 01, 2018: Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Mesoblast Ltd, Key Facts
Mesoblast Ltd, Key Employees
Mesoblast Ltd, Key Employee Biographies
Mesoblast Ltd, Major Products and Services
Mesoblast Ltd, History
Mesoblast Ltd, Other Locations
Mesoblast Ltd, Subsidiaries
Mesoblast Ltd, Key Competitors
Mesoblast Ltd, Ratios based on current share price
Mesoblast Ltd, Annual Ratios
Mesoblast Ltd, Annual Ratios (Cont.1)
Mesoblast Ltd, Interim Ratios
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Mesoblast Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Mesoblast Ltd, Performance Chart (2014 - 2018)

Mesoblast Ltd, Ratio Charts

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

CSL Ltd

Bone Medical Ltd

Alchemia Ltd

Actinogen Medical Ltd

Acrux Ltd

I would like to order

Product name: Mesoblast Ltd (MSB) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/M79A7626DDCEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M79A7626DDCEN.html>